Cytori Therapeutics Inc (CYTX) Given Average Rating of “Buy” by Analysts

Share on StockTwits

Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) have been given an average rating of “Buy” by the six brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $10.75.

A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 15th. Maxim Group reiterated a “hold” rating on shares of Cytori Therapeutics in a report on Thursday, November 15th.

NASDAQ CYTX traded down $0.01 during trading on Wednesday, hitting $0.27. 1,073 shares of the company’s stock traded hands, compared to its average volume of 511,700. Cytori Therapeutics has a 12-month low of $0.25 and a 12-month high of $3.80. The firm has a market cap of $3.60 million, a price-to-earnings ratio of -0.04 and a beta of 2.22.

Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings results on Wednesday, November 14th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.29). Cytori Therapeutics had a negative net margin of 366.48% and a negative return on equity of 202.61%. The business had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $3.24 million. During the same quarter in the previous year, the company earned ($1.40) earnings per share. Equities analysts expect that Cytori Therapeutics will post -0.99 earnings per share for the current year.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

Featured Story: Why is cost of goods sold important?

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply